Elanco Animal Health (NYSE:ELAN) Sets New 1-Year High – Still a Buy?

Elanco Animal Health Incorporated (NYSE:ELAN) shares hit a new 52-week high during trading on Tuesday . The stock traded as high as $23.00 and last traded at $22.9570, with a volume of 2100105 shares traded. The stock had previously closed at $22.27.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Weiss Ratings cut Elanco Animal Health from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday. UBS Group upped their target price on Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their target price for the company from $18.00 to $24.00 in a research report on Tuesday, October 7th. Leerink Partners upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target on the stock in a research report on Thursday, July 17th. Finally, Zacks Research lowered shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.29.

Elanco Animal Health Price Performance

The stock has a market capitalization of $11.38 billion, a P/E ratio of 381.73, a PEG ratio of 2.92 and a beta of 1.71. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The business has a fifty day simple moving average of $20.25 and a 200-day simple moving average of $16.35.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. Elanco Animal Health’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. TD Asset Management Inc lifted its position in shares of Elanco Animal Health by 289.0% during the 3rd quarter. TD Asset Management Inc now owns 1,085,823 shares of the company’s stock worth $21,868,000 after buying an additional 806,682 shares in the last quarter. Compound Planning Inc. increased its position in shares of Elanco Animal Health by 37.2% during the third quarter. Compound Planning Inc. now owns 16,436 shares of the company’s stock valued at $331,000 after acquiring an additional 4,457 shares during the last quarter. Nkcfo LLC bought a new stake in Elanco Animal Health during the third quarter worth $75,000. Ameritas Investment Partners Inc. bought a new stake in Elanco Animal Health during the third quarter worth $1,876,000. Finally, Bowen Hanes & Co. Inc. purchased a new position in Elanco Animal Health in the third quarter worth $47,626,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.